Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in KIT : A case report and literature review

KEY CLINICAL MESSAGE: We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring KIT mutations in both exons 11 and 9. The significance of this co‐occurrence is unknown and might increase the responsiveness of gastrointestinal stromal...

Descripción completa

Detalles Bibliográficos
Autores principales: Rekaya, Mariem Ben, Ksontini, Feryel, Kacem, Linda Bel Haj, Sassi, Farah, Harigua‐Souiai, Emna, Boujneh, Ryma, H'mayada, Ahmed, Zaimi, Yosra, Ayadi, Mouna, Trabelsi, Mediha, Mrad, Ridha, Rammeh, Soumaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248213/
https://www.ncbi.nlm.nih.gov/pubmed/37305871
http://dx.doi.org/10.1002/ccr3.7463
Descripción
Sumario:KEY CLINICAL MESSAGE: We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring KIT mutations in both exons 11 and 9. The significance of this co‐occurrence is unknown and might increase the responsiveness of gastrointestinal stromal tumors (GISTs) to imatinib. ABSTRACT: pCR of GIST to neoadjuvant imatinib is rare. We report a case of pCR to neoadjuvant imatinib in a gastric stromal tumor that harbored co‐occurrence of multiple KIT mutations in exons 11 and 9. This co‐occurrence in exons 9 and 11 is the first to be reported in the English literature.

Ejemplares similares